With 300k average share volume and 6 million share short it's anyones guess how far it could go. I've seen this before and mid/hi 80's is probably where it will be next week.
Look at the RGR dividend. Insider selling is systematic - not a sign things are bad.
Not sure if anything comes out of this but with public news stories coming out the people writing them aren't just making it up.
Here's why - guidance;
Reports Q1 (Sep) earnings of $1.31 per share, $0.08 better than the Capital IQ Consensus Estimate of $1.23; revenues rose 75.3% year/year to $222.6 mln vs the $219.18 mln consensus. Co issues downside guidance for Q2, sees Q2 revs of $192-208 mln vs. $208.98 mln Capital IQ Consensus Estimate.
it's GOT TO be painful for them but the 5 million plus shorties are all trying to decide who's going to run for the door first = last one out will be buying RGR over $75.
could mean nothing but that's way way bigger than ever.
........probably before earnings.
Jazz Pharmaceuticals (NASDAQ:JAZZ): After attending a Food and Drug Administration meeting on narcolepsy, Cantor Fitzgerald believes that narcolepsy patients have a high awareness and are favorably predisposed to Jazz Pharmaceuticals’s medication Xyrem. The firm reiterates a Buy rating on Jazz Pharmaceuticals’s shares.
They need to beat by at least a nickel.
maybe both....... it's a great story but with funds staying away this is individual purchasing.
partially thanks to the market but very good pattern. Not sure why jazz isn't at $120 and appreciate any input. I'm basing this purely on earnings and growth......